Recent Antiviral Chemotherapy Publications

The following list of recently published antiviral chemotherapy articles is included in this issue of Chemotherapy as a service to the scientific community. All investigators in the field are invited to send reprints of their work to assure their inclusion and the completeness of the listing.

William M. Shannon, PhD Kettering-Meyer Laboratory Southern Research Institute 2000 Ninth Avenue, South Birmingham, AL 35205 (USA)

Note: The published papers cited in this particular issue have been compiled from a single source (Ann. N.Y. Acad. Sci. 284, 1977) and resulted from the 3rd Conference on Antiviral Substances held in New York, N.Y. (USA), February 2-5, 1976 (Editor and Conference Chairman: Ernest C. Herrmann, jr., PhD).


Part I. Adenine Arabinoside


Effect of a novel adenosine deaminase inhibitor (co-vidarabine, co-V) upon the antiviral activity in vitro and in vivo of vidarabine (Vi-ra-AM) for DNA virus replication. Sloan, B. J.; Kielty, J. K., and Miller, F. A., Parke, Davis & Co., Bioj Res. and Dev., Detroit, MI 48232, USA, pp. 60-80.


Increased toxicity of 9-ß-D-arabinofuranosylade-nine in the presence of an inhibitor of adenosine deaminase. Plunkett, W. and Cohien, S. S., Univ. Texas System Cancer Ctr., M.D.


Part II. Clinical Aspects


Part III. Ribavirin


Immunosuppressive activity of ribavirin using the rabbit skin allograft model. Jolley, W. B.;
92354, USA, pp. 230-232.

Comparison of the development of resistant strains of type 1 herpes simplex virus to in vitro
antiviral activity of 5-iodo-2'-deoxyuridine or ribavirin. Huffman, J. H.; Allen, L. B., and
Sidwell, R. W., ICN Nucleic Acid Res. Inst., ICN Pharmaceuticals, Inc., Irvine, CA 92715,
USA, pp. 233-238.

Effect of ribavirin on viral hepatitis in laboratory animals. Sidwell, R. W.; Huffman, J. H.;
Campbell, N., and Allen, L. B., ICN Pharmaceuticals, Inc., Irvine, CA 92715, USA, pp. 239-246.

Effect of ribavirin on type 2 Herpesvirus hominis (HVH/2) in vitro and in vivo. Allen, L. B.,
CA 92715, USA, pp. 247-253.

The relative potencies of anti-influenza compounds. Tisdale, M. and Bauer, D. J., Wellcome Res.

Aerosol therapy of influenza infections of mice and primates with rimantadine, ribavirin, and
related compounds. Stephen, E. L.; Walker, J. S.; Dominik, J. W.; Young, H. W., and Ber-endt,

Clinical evaluation of L-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) in a double-
blind study during an outbreak of influenza. Salido-Rengell, F.; Nasser-Quinones, H., and
Mexico, SSA, Mexico City, Mexico, pp. 284-288.


Part IV. Newer Antiviral Substances

Specific inhibition of virus multiplication by bichlorinated pyrimidines. La Colla, P.; Marcialis,

A new antirhinovirus compound, ICI 73602: structure, properties, and spectrum of activity.


Synergistic effects of antiviral agents and humoral antibodies in experimental Herpesvirus

Recent studies on the antiviral and biochemical properties of 5-halo-5'-amino-deoxyribonucleo-
sides. Prusoff, W. H.; Ward, D. C.; Lin, T. S.; Chen, M. S.; Shaiu, F. T.; Chai, C; Lentz, E.,


Part V. Biochemical Studies


inhibition of poliovirus replication by a plant anti-

Recent Antiviral Chemotherapy Publications


Part VI. Antiviral Agents and Tumor Viruses


Part VII. Approaches to Discovery and Development of Antiviral Agents


Cutaneous herpes simplex virus infection of guinea pigs as a model for antiviral chemotherapy. Schäfer, T. W.; Lieberman, M.; Everett.

Recent Antiviral Chemotherapy Publications


Part VIII. Interferon Update